Barclays Sticks to Their Buy Rating for Cencora (COR)
Barclays analyst Glen Santangelo reiterated a Buy rating on Cencora yesterday. The company’s shares closed yesterday at $334.71.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Santangelo covers the Healthcare sector, focusing on stocks such as Align Tech, Cencora, and McKesson. According to TipRanks, Santangelo has an average return of 4.7% and a 50.18% success rate on recommended stocks.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Cencora with a $412.88 average price target, which is a 23.35% upside from current levels. In a report released today, TipRanks – Google also reiterated a Buy rating on the stock with a $373.00 price target.
Based on Cencora’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $85.93 billion and a net profit of $559.65 million. In comparison, last year the company earned a revenue of $81.49 billion and had a net profit of $488.6 million
Based on the recent corporate insider activity of 103 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of COR in relation to earlier this year. Last month, Robert Mauch, the President & CEO of COR sold 3,762.00 shares for a total of $1,350,332.28.
Read More on COR:
